---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066370"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:23:20.587514+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances

## Summary
- Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.
- Cash, equivalents, and securities $331M; expected to fund operations into 2028.
- MRT-6160 (VAV1) advancing to Phase 2 with Novartis; up to $2.1B in milestones.
- MRT-2359 (GSPT1) shows clinical signals in CRPC; additional data expected H2 2025.
- IND filing for MRT-8102 (NEK7) on track H1 2025; CDK2/CCNE1 IND planned for 2026.

## SEC filing metadata
- accession: 0000950170-25-066370
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/0000950170-25-066370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/glue-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066370
- JSON: https://secwatch.observer/filing/0000950170-25-066370.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.